• Home
  • Study Details
Coming Soon

Obeticholic Acid for Prevention in Barrett's Esophagus

People with Barrett's esophagus are at higher than average risk of developing esophageal cancer. Obeticholic Acid (OCA) is a medication similar to bile acids (a fluid made and released by the liver). OCA binds to a group of cells in the intestine that is believed to have a positive effect on preventing cancer development. The purpose of this study is to compare the safety and effects of OCA with that of a placebo on the risk of developing esophageal cancer in people with Barrett's esophagus.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Nicholas Shaheen
Medicine-Gastroenterology

Study Type

Clinical or Medical
Interventional

Study Topics

Stomach, Digestion and Gut Health

IRB Number

22-3141

ClinicalTrials.gov

NCT04939051

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research